Chinese Insulin Approved For Diabetes Patients In Pakistan

Web Desk — Diabetes patients in Pakistan now have a choice as the government has approved the insulin glargine injections developed by a Chinese pharmaceutical company.

It is the first insulin glargine injection (prefilled injection pen) biosimilar drug in Pakistan, according to the company.

For the treatment of diabetes, insulin glargine injection is an essential long-acting insulin analog product for its efficacy and safety.

Diabetes in Pakistan

In terms of diabetic patients, Pakistan is ranked third in the world after China and India with approximately 33 million people aged 20-79 in 2021. As per the latest data released by the International Diabetes Federation (IDF), the prevalence of diabetes among adults aged 20-79 in Pakistan is 30.8 percent, the highest in the world.

According to an estimate, the overall market for insulin in Pakistan is over $50 million. Sanofi, Novo Nordisk, and Eli Lilly take the majority of the market share and now the Chinese product will bring more quality options to Pakistani diabetic patients.